XML 128 R99.htm IDEA: XBRL DOCUMENT v3.24.1
Share-Based Payments - Additional Information (Details)
€ / shares in Units, $ / shares in Units, € in Millions
1 Months Ended 12 Months Ended
Aug. 19, 2019
Aug. 18, 2017
USD ($)
$ / shares
May 31, 2022
EUR (€)
May 31, 2021
EUR (€)
Sep. 30, 2019
EUR (€)
shares
€ / shares
Sep. 30, 2019
USD ($)
shares
$ / shares
Dec. 31, 2023
EUR (€)
shares
€ / shares
Dec. 31, 2023
USD ($)
shares
$ / shares
Dec. 31, 2022
EUR (€)
shares
€ / shares
Dec. 31, 2021
EUR (€)
shares
Dec. 31, 2020
Oct. 09, 2023
shares
Jan. 31, 2023
EUR (€)
May 30, 2022
shares
May 17, 2021
shares
May 12, 2021
shares
Feb. 29, 2020
shares
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Share-based payments             € (766.2)   € (51.8) € (13.4)              
Cash outflow to tax authority             213.0                    
Liabilities from share-based payment arrangements             € 29.0   € 36.2                
Applicable wage taxes and social security contributions resulting from and withheld upon exercise                         € 724.0        
LTI Program                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)                 4 years 4 years 4 years            
Weighted average share price (in euros per share) | € / shares             € 171.40                    
LTI-plus program                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)                 2 years                
Share options outstanding (in shares) | shares             0   0 372,011              
BioNTech 2020 Restricted Stock Unit Plan For North America Employees                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)                     4 years            
Cash outflow for share based payment exercise             € 10.0   € 9.4 € 10.1              
Liabilities from share-based payment arrangements             € 14.4   13.4                
BioNTech 2020 Restricted Stock Unit Plan For North America Employees | One year                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Vesting percentage after one year (as a percent)                     25.00%            
Management Board Grant                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)             4 years 4 years                  
Liabilities from share-based payment arrangements             € 2.1   € 2.3                
Percentage of ADS to ordinary shares (as a percent)             50.00% 50.00%                  
Option rights exercisable period (in years)         10 years 10 years 4 years 4 years                  
Percentage of exercise price increase (as a percent)             7.00% 7.00%                  
Threshold amount of dividend by number of shares outstanding immediately following initial public offering             € 8,500.0                    
Percentage of target share price applicable for prior twelve month period (as a percent)             107.00% 107.00%                  
Reclassification for share-based payment arrangement     € 3.3 € 1.1                          
Price of ADS as a percentage of exercise price, maximum (as a percent)                                 800.00%
Maximum economic benefits of options exercised | $               $ 246.24                  
Effective exercise price maximum (in dollars per share) | $ / shares               $ 30.78                  
Options outstanding, weighted-average expected life (in years)             4 years 1 month 6 days 4 years 1 month 6 days 4 years                
Liability related to the phantom option awards             € 3.6   € 5.6                
Share options outstanding (in shares) | shares                           86,118 6,463 45,279 248,096
Management Board Grant | Prof. Ugur Sahin, M.D.                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Maximum cash payment             20.0                    
Management Board Grant | Sierk Poetting, Ph.D.                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Maximum cash payment             € 10.0                    
Chief Executive Officer Grant                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Percentage of exercise price increase (as a percent)         7.00% 7.00%                      
Price of ADS as a percentage of exercise price, maximum (as a percent)         800.00% 800.00%                      
Maximum economic benefits of options exercised | $           $ 240.00                      
Effective exercise price maximum (in dollars per share) | $ / shares           $ 30.00                      
Options outstanding, weighted-average expected life (in years)             1 year 1 month 6 days 1 year 1 month 6 days 2 years 1 month 6 days                
Chief Executive Officer Grant | Ordinary shares                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)         4 years 4 years                      
Option rights exercisable period (in years)         4 years 4 years                      
Threshold amount of dividend by number of shares outstanding immediately following initial public offering         € 8,500.0                        
Percentage of target share price applicable for prior twelve month period (as a percent)         107.00% 107.00%                      
Option to purchase ordinary shares (in shares) | shares         4,374,963 4,374,963                      
Exercise price in translation for IPO (in dollar per share and euro per share) | (per share)         € 13.60 $ 15.00                      
Chief Executive Officer Grant | Ordinary shares | Maximum                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights exercisable period (in years)         10 years 10 years                      
Employee Stock Ownership Plan                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Percentage of exercise price increase (as a percent) 7.00% 8.00%                              
Price of ADS as a percentage of exercise price, maximum (as a percent)   800.00%                              
Maximum economic benefits of options exercised | $   $ 240                              
Effective exercise price maximum (in dollars per share) | $ / shares   $ 30.00                              
Options outstanding, weighted-average expected life (in years)             9 months 18 days 9 months 18 days 1 year 8 months 12 days                
Number of share options exercisable in share-based payment arrangement (in shares) | shares                       4,374,963          
Minimum strike price (as a percent) 28.00% 32.00%                              
Cash-settled option rights, exercised (in shares) | shares             39,785 39,785 583,383                
Weighted average share price (in euros per share) | € / shares             € 96.49   € 160.44                
Share options outstanding (in shares) | shares             17,799   57,584 642,007              
Employee Stock Ownership Plan | Ordinary shares                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Option rights vesting period (in years)   4 years                              
Option rights exercisable period (in years)   4 years                              
Cash-Settled Share-Based Payment Arrangement | Employee Stock Option Plan                                  
Disclosure of terms and conditions of share-based payment arrangement [line items]                                  
Liabilities from share-based payment arrangements             € 8.5   € 14.5                
Exercise price of phantom options granted (in euro per share) | € / shares                 € 10.14                
Cash-settled option rights, exercised (in shares) | shares             52,100 52,100 289,168                
Cash outflow             € 4.5   € 42.2                
Weighted average share price (in euros per share) | € / shares             € 96.25   € 155.39                
Share options outstanding (in shares) | shares             109,651                    
Cash-settled related to rights vested and exercisable             € 8.3   € 11.2